Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:26:52.688Z.
Calculation as of: 2026-10-06T19:26:52.688Z.
Quote observation: 2026-10-06T19:25:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$2.35B
Price/FCF Ratio
20.15
TTM Avg
65.29
3Y Avg
92.84
5Y Avg
92.84
Market Cap
$2.40B
Price/FCF Ratio
32.37
TTM Avg
38.73
3Y Avg
40.68
5Y Avg
38.72
Market Cap
$2.42B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.33B
Price/FCF Ratio
N/A
TTM Avg
126.91
3Y Avg
126.91
5Y Avg
126.91
Market Cap
$2.33B
Price/FCF Ratio
37.97
TTM Avg
25.12
3Y Avg
37.59
5Y Avg
73.49
Market Cap
$2.30B
Price/FCF Ratio
37.96
TTM Avg
109.25
3Y Avg
109.25
5Y Avg
109.25
Market Cap
$2.46B
Price/FCF Ratio
131.17
TTM Avg
56.89
3Y Avg
28.15
5Y Avg
23.49
Market Cap
$2.28B
Price/FCF Ratio
6.43
TTM Avg
6.22
3Y Avg
8.21
5Y Avg
14.22
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.38B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.35B | 20.15 | 65.29 | 92.84 | 92.84 |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 32.37 | 38.73 | 40.68 | 38.72 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | N/A | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.33B | N/A | 126.91 | 126.91 | 126.91 |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 37.97 | 25.12 | 37.59 | 73.49 |
| Liquidia Corporation (LQDA)vs › | $2.30B | 37.96 | 109.25 | 109.25 | 109.25 |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.46B | 131.17 | 56.89 | 28.15 | 23.49 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 6.43 | 6.22 | 8.21 | 14.22 |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.52B | N/A | 8.31 | 8.31 | 8.31 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
